Full-Time

Executive Director

Portfolio Management Office

Posted on 11/27/2024

Acadia Pharmaceuticals

Acadia Pharmaceuticals

501-1,000 employees

Develops therapies for neurological disorders

Biotechnology
Healthcare

Compensation Overview

$246.5k - $308.1kAnnually

+ Bonus + Equity Awards

Senior

Princeton, NJ, USA

Hybrid model requires in-office presence three days per week on average.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree in a related field; Advanced degree preferred.
  • Targeting 15 years of progressively responsible, relevant experience focusing on program management with 10 years in a leadership role which includes leading and managing project manager and teams.
  • Strong understanding of project management roles specifically in the pharmaceutical industry and/or other technically based, regulated research and development environment.
  • Experience in developing and implementing project and portfolio management methodologies and tools.
  • Strong strategic thinking and leadership skills.
  • Seasoned communication skills and executive presence.
  • Broad knowledge of project and portfolio management processes in support of drug development in the pharmaceutical industry.
  • Advanced meeting facilitation skills and ability to lead cross-functional teams.
  • Ability to accommodate and lead teams through shifting priorities, demands and timelines.
  • Ability to elicit cooperation from a wide variety of sources and to be persuasive, encouraging and motivating.
  • Adept at creating and communicating a clear vision for a program among team members to facilitate alignment of resources to achieve program and corporate goals.
  • Proven track record of implementing Project Management tools, including SmartSheet, and deep experience with Microsoft Project and Microsoft SharePoint.
Responsibilities
  • Development, implementation, and management of project and portfolio management standards, processes, and tools to support Asset Strategy Team delivery as well as portfolio-level oversight, strategy development, and decision making.
  • Management of PMO program management staff that will support teams and be responsible for the entry and quality oversight of project management data captured in the project and portfolio management systems.
  • Providing recurring and ad hoc reporting, along with analysis, to senior management in support of managing the portfolio of Asset Team programs at Acadia.
  • Optimization of lifecycle management operating model and governances.
  • Work with functional areas to link and visualize project management data managed in functions to the Asset Team and Franchise plans as needed to support efficient and effective cross-functional delivery of Asset Team Programs.
  • Leading Projects in support of the portfolio as needed.
  • Other duties as assigned.
Acadia Pharmaceuticals

Acadia Pharmaceuticals

View

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Company Stage

Acquired

Total Funding

$813.4M

Headquarters

Dallas, Texas

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Acadia's launch of Magnolia's Guide to Adventuring showcases their innovative approach to raising disease awareness and redefining perceptions of Rett syndrome.
  • The acceptance of trofinetide for priority review by Health Canada could lead to significant market expansion and first-mover advantage in treating Rett syndrome in Canada.
  • The appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development, signals a strong commitment to advancing their R&D capabilities.

What critics are saying

  • The failure of the Phase III ADVANCE-2 trial for pimavanserin in schizophrenia highlights the high-risk nature of drug development in the biopharmaceutical sector.
  • Dependence on regulatory approvals, such as the FDA and Health Canada, introduces uncertainty and potential delays in bringing therapies to market.

What makes Acadia Pharmaceuticals unique

  • Acadia Pharmaceuticals focuses exclusively on neurological disorders, setting it apart from competitors with broader therapeutic areas.
  • Their commitment to corporate social responsibility, including initiatives like the Rett Sibling Scholarship, enhances their reputation and community engagement.
  • Acadia's strategic partnerships and corporate sponsorships amplify their research capabilities and market reach, distinguishing them from competitors who may not leverage such collaborations.

Help us improve and share your feedback! Did you find this helpful?